Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | HTR6 | P50406 | 4/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519153 | 0.94 | SIRT6 (0.67) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL375616 | 0.93 | SIRT6 (0.77) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL2062143 | 0.89 | SIRT6 (0.77) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL15754980 | 0.88 | LMNA (0.64) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL23534178 | 0.86 | SIRT6 (0.65) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL29709935 | 0.86 | SIRT6 (0.65) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL520231 | 0.84 | ALDH1A1 (0.76) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL520015 | 0.83 | SIRT6 (1.00) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL311491 | 0.83 | ALDH1A1 (0.74) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL519977 | 0.82 | ALDH1A1 (0.60) | SIRT6ALDH1A1LMNAMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | SIRT6 4245/4885ALDH1A1 3512/4885LMNA 2407/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | SIRT6 4245/4885ALDH1A1 3512/4885LMNA 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.